AKEBIA THERAPEUTICS, INC. License and Services Revenue (Deprecated 2018-01-31)
AKEBIA THERAPEUTICS, INC. (AKBA) reported License and Services Revenue (Deprecated 2018-01-31) of $45.93 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2018-05-09
- AKEBIA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $45.93M, a 120.13% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $87.32M, a 5588.34% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $41.28M.
- AKEBIA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $28.52M.
- AKEBIA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $177.98M, a 11495.05% increase from fiscal 2016.
- AKEBIA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $1.53M.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $45.93M 10-Q · filed 2018-05-09 | $133.25M derived: sum of 2 quarters · filed 2018-05-09 | $174.53M derived: sum of 3 quarters · filed 2018-05-09 | $203.05M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $87.32M 10-K · filed 2018-03-12 | $128.60M derived: sum of 2 quarters · filed 2018-03-12 | $157.12M derived: sum of 3 quarters · filed 2018-03-12 | $177.98M 10-K · filed 2018-03-12 |
| 2017-09-30 | $41.28M 10-K · filed 2018-03-12 | $69.80M derived: sum of 2 quarters · filed 2018-03-12 | $90.67M 10-Q · filed 2017-11-08 | $92.20M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $28.52M 10-K · filed 2018-03-12 | $49.38M 10-Q · filed 2017-08-08 | $50.92M derived: sum of 3 quarters · filed 2018-05-09 | |
| 2017-03-31 | $20.86M 10-Q · filed 2018-05-09 | $22.40M derived: sum of 2 quarters · filed 2018-05-09 | ||
| 2016-12-31 | $1.53M 10-K · filed 2018-03-12 | $1.53M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |